Australian TGA adds NAION blindness warning to GLP-1 receptor agonist labels

The Australian Therapeutic Goods Administration has mandated label updates for GLP-1 medications, including Ozempic and Mounjaro, to include warnings regarding non-arteritic anterior ischemic optic neuropathy (NAION). This rare but severe eye disorder carries a risk of permanent vision loss, marking a significant regulatory shift in the safety profile of these widely used diabetes and weight-loss drugs.